Journal of Translational Medicine

Table 4 Expression of typical DC surface markers

From: Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission

	CD14						CD40						CD80						CD83
% positive cells	HD			AML			HD			AML			HD			AML			HD			AML
C	1	±	1	0	±	0	100	±	0	99	±	1	100	±	0	98	±	3	100	±	0	100	±	0
CP	3	±	4	2	±	4	99	±	1	97	±	9	99	±	1	98	±	4	97	±	9	95	±	10
R	0	±	0	1	±	1	100	±	0	90	±	15	100	±	0	100	±	0	100	±	0	100	±	0
RP	8	±	9	1	±	0	99	±	2	90	±	10	99	±	2	100	±	0	100	±	1	100	±	1
MFIs
C	2	±	1	1	±	1	22	±	2	27	±	1	108	±	2	61	±	4	41	±	2	35	±	2
CP	2	±	1	2	±	1	19	±	1	15	±	2	87	±	2	55	±	2	36	±	2	27	±	2
R	2	±	1	2	±	1	22	±	2	12	±	2	129	±	1	73	±	2	60	±	1	39	±	1
RP	3	±	2	2	±	1	33	±	2	13	±	2	98	±	2	80	±	2	43	±	2	52	±	1
	CD86						CD274						CCR7						HLA-DR
% positive cells	HD			AML			HD			AML			HD			AML			HD			AML
C	100	±	0	94	±	14	79	±	44	78	±	40	66	±	37	71	±	22	100	±	0	100	±	0
CP	100	±	1	90	±	25	99	±	2	97	±	5	76	±	25	81	±	14	100	±	0	99	±	2
R	100	±	0	100	±	0	84	±	16	98	±	3	66	±	35	80	±	13	89	±	16	100	±	0
RP	99	±	1	100	±	0	89	±	11	99	±	2	65	±	33	73	±	20	99	±	1	100	±	0
MFIs
C	87	±	2	46	±	5	10	±	4	8	±	3	5	±	3	6	±	2	278	±	1	327	±	1
CP	80	±	2	49	±	4	24	±	1	17	±	2	8	±	3	18	±	4	273	±	1	171	±	2
R	136	±	1	96	±	2	14	±	2	23	±	4	6	±	2	7	±	2	209	±	2	223	±	2
RP	92	±	2	71	±	3	12	±	2	17	±	1	6	±	3	9	±	2	540	±	1	215	±	2

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com